Davis George Eric 4
4 · BIOMARIN PHARMACEUTICAL INC · Filed Feb 27, 2025
Insider Transaction Report
Form 4
Davis George Eric
EVP, Chief Legal Officer
Transactions
- Award
Common Stock
2025-02-25+11,040→ 67,197 total - Award
Common Stock
2025-02-25+9,660→ 76,857 total - Award
Common Stock
2025-02-25+9,367→ 86,224 total
Footnotes (5)
- [F1]Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis.
- [F2]Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return during 2022 through 2024 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.
- [F3]Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2025, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events.
- [F4]Represents the total number of RSUs earned pursuant to a formula based on the number and nature of development goals achieved during 2022 through 2024 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.
- [F5]Represents the total number of RSUs earned pursuant to a formula based on core operating margin over three, one-year periods spanning 2022 through 2024 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.